<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346811</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IC-IV90</org_study_id>
    <nct_id>NCT03346811</nct_id>
  </id_info>
  <brief_title>Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer</brief_title>
  <acronym>CHALLENGE</acronym>
  <official_title>Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer：a Single Arm，Multi-center，Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib
      in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2017</start_date>
  <completion_date type="Anticipated">March 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>12 months</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>20 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Plasma EGFR Mutation-positive Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity</description>
    <arm_group_label>Experimental: icotinib</arm_group_label>
    <other_name>conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of peripheral lung cancer, but the pathological diagnosis is not
             yet clear.

          -  Plasma EGFR mutations (EGFR 19del and/or 21L858R) positive (simultaneously detected by
             Super-ARMS, ddPCR and NGS，any positive).

          -  unavailable of radical surgery or radical radiotherapy.

          -  not previously received anticancer therapy like surgery, chemotherapy, radiation
             therapy, and biotherapy etc.

          -  Palliative radiotherapy for bone metastases is permitted, but there is no continuous
             toxicity associated with radiation therapy.

          -  Age 18-75 years old with performance status of 0 to 3.

          -  With a measurable disease(longest diameters &gt;=10mm with Spiral computed tomography
             (CT)) according to RECIST Criteria.None of the lesions treated with radiotherapy could
             be used as target lesions.

          -  Adequate hematological, biochemical and organ functions.

        Exclusion Criteria:

          -  Severe systemic disease out of control such as unstable or uncompensated
             respiratory,cardiac,liver,renal diseases.

          -  Evidence of interstitial lung diseases

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the study

          -  Other situations researchers think not appropriate to enter the group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Wang, MD</last_name>
    <phone>13910704669</phone>
    <email>zlhuxi@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhijie Wang, MD</last_name>
    <phone>13466323860</phone>
    <email>jie_969@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wang, MD</last_name>
      <phone>13910704669</phone>
      <email>zlhuxi@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhijie Wang, MD</last_name>
      <phone>13466323860</phone>
      <email>jie_969@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

